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Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a complex condition. Causal factors
are not established, although underlying psychological or immunological susceptibility has been proposed. We
studied primary care diagnoses for children with CFS/ME, with children with another hospital diagnosis (type 1
diabetes mellitus [T1DM]) and the general child population as comparison groups.
Methods: All Norwegian children born 1992–2012 constituted the study sample. Children with CFS/ME (n = 1670)
or T1DM (n = 4937) were identified in the Norwegian Patient Register (NPR) (2008-2014). Children without either
diagnosis constituted the general child population comparison group (n = 1337508). We obtained information on
primary care diagnoses from the Norwegian Directorate of Health. For each primary care diagnosis, the proportion
and 99 % confidence interval (CI) within the three groups was calculated, adjusted for sex and age by direct
standardization.
Results: Children with CFS/ME were more often registered with a primary care diagnosis of weakness/general
tiredness (89.9 % [99 % CI 88.0 to 91.8 %]) than children in either comparison group (T1DM: 14.5 % [99 % CI: 13.1
to 16.0 %], general child population: 11.1 % [99 % CI: 11.0 to 11.2 %]). Also, depressive disorder and anxiety disorder
were more common in the CFS/ME group, as were migraine, muscle pain, and infections. In the 2 year period prior
to the diagnoses, infectious mononucleosis was registered for 11.1 % (99 % CI 9.1 to 13.1 %) of children with CFS/
ME and for 0.5 % (99 % CI (0.2 to 0.8 %) of children with T1DM. Of children with CFS/ME, 74.6 % (1292/1670) were
registered with a prior primary care diagnosis of weakness / general tiredness. The time span from the first primary
care diagnosis of weakness / general tiredness to the specialist health care diagnosis of CFS/ME was 1 year or
longer for 47.8 %.
Conclusions: This large nationwide registry linkage study confirms that the clinical picture in CFS/ME is complex.
Children with CFS/ME were frequently diagnosed with infections, supporting the hypothesis that infections may be
involved in the causal pathway. The long time span often observed from the first diagnosis of weakness / general
tiredness to the diagnosis of CFS/ME might indicate that the treatment of these patients is sometimes not optimal.
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Abbreviations: CFS, Chronic fatigue syndrome; CI, Confidence interval; ICD-10, International Classification of
Disease, Version 10; ICPC-2, International Classification of Primary Care, Second Edition; ME, Myalgic
encephalomyelitis; NPR, Norwegian Patient Register; T1DM, Type 1 diabetes mellitusBackground
Chronic fatigue syndrome (CFS), or myalgic encephalo-
myelitis (ME), is a debilitating disorder, characterized by
severe fatigue of unknown cause and often accompanied
by other symptoms such as muscle pain and headache
[1, 2]. The terms CFS and ME are often used interchange-
ably, and Norwegian health authorities recommend using
the combined term CFS/ME [3]. In addition to fatigue,
CFS/ME is associated with symptoms such as post-
exertional malaise, pain, unrefreshing sleep, and cognitive
impairment [1]. We have previously shown that CFS/ME
is threefold more common among women than among
men, with highest incidence rates among children and
adolescents aged 10 to 19 years [4].
In Norway, children with possible CFS/ME are routinely
referred by their general practitioner to hospital for diag-
nostic workup, while follow-up after diagnosis is the re-
sponsibility of the general practitioner. In the present
population-based registry study we have used data from
Norwegian primary and specialist health care registries
with national coverage to further investigate the burden of
CFS/ME in children. The study had two main objectives.
Our first aim was to describe comorbidities diagnosed in
primary care in children diagnosed with CFS/ME in
specialist health care with children in the general popula-
tion as control group. As treatment-seeking study-samples
may be different from the general population in terms of
registered comorbidities, we also used a comparison group
of children with a chronic disease, type 1 diabetes mellitus
(T1DM). Our second aim was to describe the timing of
the diagnoses from primary care in relation to the timing
of the CFS/ME diagnosis.
Methods
Study setting
Norway has a nationwide public health care system. Access
to specialists requires referral from a general practitioner.
The system is financed through governmental funding, and
health care is free of charge for children up to the age of
16 years. Outpatients aged 16 years and up pay a minor
fee, while all hospitalizations are free of charge.
Data sources and definition of study groups
We linked data from national registries and health data-
bases by using the unique 11-digit personal identification
number provided to all Norwegian residents.
Children with CFS/ME and children with T1DM were
identified through the Norwegian Patient Register (NPR)[5]. This registry contains data from all Norwegian
hospitals and outpatient clinics. Reporting to the NPR
is mandatory and is linked to the reimbursement sys-
tem. Discharge diagnoses are reported as International
Classification of Disease, Version 10 (ICD-10) codes.
Administrative data reported include the patient’s personal
identification number and dates for hospitalization and
discharge.
The Norwegian Directorate of Health reimburses con-
sultations in general practice. Diagnoses are reported as
International Classification of Primary Care, Second
Edition (ICPC-2) codes, together with the patient’s per-
sonal identification number and the date of consultation.
We had access to information on a range of ICPC-2
codes for all Norwegian residents for the time period
2006–2014.
The study population was identified by using data
from the National Registry and included children and
adolescents (hereafter referred to as “children”) resident
in Norway during 2008–2014. The children were followed
through the calendar year they turned 18 years. To allow
for a follow-up window of at least 2 years, we included
children who were born between 1992 and 2012 to the
study population.
Children were defined as having CFS/ME if they were
registered as in- or outpatients in Norwegian hospitals
with the ICD-10 code G93.3 (“postviral fatigue syndrome/
benign myalgic encephalomyelitis”). Similarly, children
were defined as having T1DM if they were registered as
in- or outpatients in Norwegian hospitals with ICD-10
code E10 (“type 1 diabetes mellitus”). In the total study
sample of 1344133 children born 1992–2012 and resident
in Norway during 2008–2014, we identified 1670 children
with CFS/ME but not T1DM and 4937 children with
T1DM but not CFS/ME (Fig. 1). A total of 18 children
registered with both CFS/ME and T1DM were excluded
from the study population. This left 1 337 508 children
not registered with CFS/ME or T1DM before the age of
18 years for the general child population control group.
Statistical analysis
For each ICPC-2 diagnosis, the proportion of children
registered was calculated in each group. Proportions
were adjusted for sex and age by direct standardization,
using the CSF/ME group as the standard population.
Non-overlapping confidence intervals (99 %) show sta-
tistically significant differences in proportions. With the
exception of the ICPC-2 codes for diabetes (T89/T90),
Fig. 1 Study flow chart. A flow diagram illustrating the selection of the
study groups
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with CFS/ME were included to the analyses.
The Stata software package, Version 13.1 (StataCorp.
2013. Stata Statistical Software: Release 13. College Station,
TX, USA: StataCorp LP) was used for data analysis.
Results
The mean age at CFS/ME diagnosis among the 1670
children registered at least once in specialist health care
with this diagnosis was 14.8 years (standard deviation
[SD] 2.5 years) and 66.7 % were girls. Mean age at first
diagnosis among the 4937 children in the T1DM control
group was 10.9 years (SD 4.2 years) and 46.5 % were
girls. The general child population control group con-
sisted of 1 337 508 children (48.7 % girls).
Diagnoses from primary care
Table 1 shows the proportions of children in each group
registered with the primary care diagnoses.
Among children with CFS/ME, the most frequently
observed primary care diagnosis was “weakness / gen-
eral tiredness” (ICPC-2 code A04). This diagnosis was
registered for 89.9 % of children in the CFS/ME group,
14.5 % in the T1DM group, and 11.1 % in the general
child population group. “Neurasthenia” (ICPC-2 code
P78) and “sleep disturbance” (ICPC-2 code P06) are
other codes that are closely related to CFS/ME. Neuras-
thenia was hardly ever used as a diagnosis for children
in the two control groups, while 9.3 % of the children
in the CFS/ME group had this diagnosis. Sleep disturb-
ance was also far more frequent in the CFS/ME group,
as was muscle pain (CFS/ME: 9.5 %, T1DM: 3.8 %,
general child population: 2.3 %).
Furthermore, we found higher frequencies of depres-
sion and anxiety in the CFS/ME group (13.8 and 4.4 %,
respectively) than in the T1DM (corresponding figures:5.4 and 1.8 %) and general child population control
groups (corresponding figures: 2.7 and 1.1 %).
Elevated frequencies of all diagnoses related to infec-
tion were observed in the CFS/ME group. In particular,
infectious mononucleosis was far more frequent in this
group (17.2 %) than in the control groups (T1DM:
3.7 %, general child population: 2.9 %). Influenza, acute
tonsillitis, “strep throat”, and pneumonia were also more
frequent in the CFS/ME group.
While ICPC-2 codes for diabetes were registered for
86.0 % of children in the T1DM group, these codes were
rarely registered for children without a specialist health
care diagnosis of T1DM (CFS/ME group and general
child population).
Asthma was also more common in the CFS/ME group
(17.5 %) than in the two control groups (11 % in both
groups).
Timing of the diagnoses
Comparing only primary care diagnoses within the 2 years
prior to the specialist health care diagnoses revealed even
stronger differences between the CFS/ME group and the
T1DM group (Table 2).
For instance, while 73.4 % of the CFS/ME patients had
been diagnosed with weakness / general tiredness prior
to their CFS/ME diagnosis, this was the case for only
3.5 % of T1DM patients. Similar results were found for
muscle pain, depression, anxiety, and migraine. Also,
strong differences were found between the CFS/ME
group and the T1DM group for diagnoses related to in-
fection. While 11.1 % of children with CFS/ME had been
diagnosed with infectious mononucleosis prior to the
specialist health care diagnosis, this was the case for
0.6 % of children with T1DM. Other diagnoses related to
infections (influenza, acute tonsillitis, “strep throat” and
pneumonia) were 2–3 times more common in the CFS/
ME group than in the T1DM group.
Time from first diagnosis of weakness / general tiredness
to CFS/ME diagnosis
Among the 1670 children with CFS/ME, 1292 (74.6 %)
were registered with at least one prior primary care diag-
nosis of weakness / general tiredness (follow-up 2006–
2014). A total of 782 (46.8 %) were registered at least
four times with this diagnosis. For a large proportion of
children with a prior weakness / general tiredness diag-
nosis, the time span to the CFS/ME diagnosis was 1 year
or longer (617/1292, 47.8 %).
Discussion
In this large, population-based study, children and
adolescents with CFS/ME were significantly more often
diagnosed with several conditions in primary care than
children with T1DM and children in the general
Table 1 Proportion registered with primary care diagnoses among children with CFS/ME or type 1 diabetes mellitus (T1DM) in



















Diagnoses related to CFS/ME
Weakness / general tiredness (A04) 1501 89.9 (88.0–91.8) 666 14.5 (13.1–16.0) 140 915 11.1 (11.0–11.2)
Neurasthenia (P78) 156 9.3 (7.5–11.2) 2 0.0 (0.0–0.1) 1220 0.1 (0.1–0.1)
Sleep disturbance (P06) 258 15.4 (13.2–17.7) 204 4.1 (3.3–4.9) 43 795 3.3 (3.2–3.3)
Muscle pain (L18) 159 9.5 (7.7–11.4) 173 3.8 (3.0–4.6) 29 242 2.3 (2.3–2.4)
Common mental disorders
Depressive disorder (P76) 230 13.8 (11.6–15.9) 231 5.4 (4.4–6.3) 32 399 2.7 (2.7–2.8)
Anxiety disorder/anxiety state (P74) 73 4.4 (3.1–5.7) 83 1.8 (1.3–2.4) 13 347 1.1 (1.1–1.1)
Diagnoses related to infections
Influenza (R80) 412 24.7 (22.0–27.4) 739 15.1 (13.6–16.5) 133 281 10.1 (10.0–10.1)
Infectious mononucleosis (A75) 288 17.2 (14.9–19.6) 164 3.7 (2.9–4.5) 35 662 2.9 (2.8–2.9)
Tonsillitis acute (R76) 313 18.7 (16.3–21.2) 577 12.3 (11.0–13.6) 162 526 12.3 (12.3–12.4)
Strep throat (R72) 236 14.1 (11.9–16.3) 483 9.9 (8.7–11.0) 126 394 9.6 (9.5–9.6)
Pneumonia (R81) 207 12.4 (10.8–14.5) 356 7.3 (6.2–8.3) 90 027 6.7 (6.6–6.7)
Other diagnoses
Diabetes (T89/T90) 1 0.1 (0.0–0.2) 4238 86.0 (84.6–87.4) 1079 0.1 (0.1–0.1)
Asthma (R96) 292 17.5 (15.1–19.9) 579 11.3 (10.1–12.6) 161 103 11.5 (11.4–11.6)
Migraine (N89) 187 11.2 (9.2–13.2) 128 3.0 (2.3–3.7) 30 255 2.5 (2.5–2.5)
Hyperkinetic disorder (P81) 54 3.2 (2.1–4.3) 175 3.0 (2.4–3.6) 37 387 2.4 (2.4–2.5)
Congenital anomaly musculoskeletal (L82) 54 3.2 (2.1–4.3) 89 1.8 (1.3–2.3) 28 096 2.0 (2.0–2.1)
Child behaviour symptom/complaint (P22) 71 4.3 (3.0–5.5) 143 2.7 (2.1–3.4) 37 241 2.5 (2.5–2.5)
Psychological disorders, other (P99) 55 3.3 (2.2–4.4) 95 1.9 (1.3–2.4) 17 008 1.2 (1.2–1.2)
Endocrine/metabolic/nutritional disorder,
other (T99)
65 3.9 (2.7–5.1) 152 3.4 (2.7–4.2) 21 051 1.7 (1.7–1.7)
Proportions were adjusted for sex and age group (3-year categories) by direct standardization, using the population with CFS/ME as the reference population
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tions closely related to CFS/ME but also depression,
anxiety, infections, and migraine. When restricting to
primary care diagnoses prior to the specialist health
care diagnoses, even stronger differences between chil-
dren with CFS/ME and children with T1DM were
observed. Three out of four children with CFS/ME in
specialist health care were registered with a prior diag-
nosis of weakness / general tiredness in primary care.
However, as we had access to specialist health care
diagnoses for the period 2008–2014 and primary care
diagnoses only from 2006 to 2014, it cannot be ruled
out that the proportion with this diagnosis in primary
care was even higher. For many children the time span
from the first primary care diagnosis of weakness /
general tiredness to the first CFS/ME diagnosis was
1 year or longer.
CFS/ME is a rare disease and previous studies have
typically included small number of patients. The mainstrength of this study is the utilization of registry data
covering the entire population over a long study period.
Children with a serious condition of prolonged nature
(in this case CFS/ME) are likely to be followed up more
closely in primary care than children without such a
condition. By including a control group with another
chronic condition (T1DM) we were able to make com-
parisons of children with CFS/ME both to the general
child population and to a chronic condition group.
As in other studies based on observational, routinely
collected data, a major limitation is the lack of validity
testing of the diagnoses. While ICD-10 code G93.3 is to
be used for CFS/ME in specialist health care, there is no
specific ICPC-2 code for the condition that is to be used
in primary care. The observation that children diagnosed
with CFS/ME in specialist health care were far more
often registered with the ICPC-2 code for weakness /
general tiredness in primary care than children with
T1DM and children in the general child population is
Table 2 Proportion registered with primary care diagnoses within the period 2 years prior to the first registered CFS/ME or type 1





# with condition Proportion
% (99 % CI)
# with condition Proportion
% (99 % CI)
Diagnoses related to CFS/ME
Weakness / general tiredness (A04) 1226 73.4 (70.6–76.2) 164 3.5 (2.8–4.3)
Neurasthenia (P78) 58 3.5 (2.3–4.6) 1 0.0 (0.0–0.1)
Sleep disturbance (P06) 94 5.6 (4.2–7.1) 42 0.9 (0.5–1.2)
Muscle pain (L18) 59 3.5 (2.4–4.7) 37 0.8 (0.4–1.2)
Common mental disorders
Depressive disorder (P76) 94 5.6 (4.2–7.1) 19 0.4 (0.1–0.6)
Anxiety disorder/anxiety state (P74) 19 1.1 (0.5–1.8) 15 0.3 (0.1–0.5)
Diagnoses related to infections
Influenza (R80) 173 10.4 (8.4–12.3) 154 3.1 (2.4–3.8)
Infectious mononucleosis (A75) 185 11.1 (9.1–13.1) 25 0.5 (0.2–0.8)
Tonsillitis acute (R76) 85 5.1 (3.7–6.5) 161 3.4 (2.6–4.1)
Strep throat (R72) 74 4.4 (3.1–5.7) 123 2.5 (1.8–3.1)
Pneumonia (R81) 83 5.0 (3.6–6.3) 107 2.2 (1.6–2.8)
Other diagnoses
Diabetes (T89/T90) 0 0.0 (0.0–0.0) 1 362 28.2 (26.4–29.9)
Asthma (R96) 134 8.0 (6.3–9.7) 253 5.0 (4.1–5.8)
Migraine (N89) 102 6.1 (4.6–7.6) 30 0.6 (0.3–0.8)
Hyperkinetic disorder (P81) 35 2.1 (1.2–3.0) 73 1.2 (0.8–1.6)
Congenital anomaly musculoskeletal (L82) 19 1.1 (0.5–1.8) 32 0.7 (0.3–1.0)
Child behaviour symptom/complaint (P22) 32 1.9 (1.1–2.8) 52 1.0 (0.6–1.4)
Psychological disorders, other (P99) 22 1.3 (0.6–2.0) 17 0.3 (0.1–0.5)
Endocrine/metabolic/nutritional disorder, other (T99) 18 1.1 (0.4–1.7) 54 1.3 (0.8–1.7)
Proportions were adjusted for sex and age group (3-year categories) by direct standardization, using the population with CFS/ME as the reference population
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diagnosis from specialist health care. Similarly, ICPC-2
codes for diabetes were registered in primary care for
most children with the ICD-10 code for T1DM in spe-
cialist health care, but only for a small proportion of the
children in the two other groups. The Norwegian Direct-
orate of Health recommends use of the ICD-10 code
G93.3 for CFS/ME [3]. Still, some children fulfilling
criteria for a diagnosis of CFS/ME might have been
registered with other ICD-10 codes. In a recent study,
paediatricians generally reported that they follow the
guidelines of the Norwegian Paediatric Association [6].
In the present study we found a high frequency of be-
ing diagnosed with depression among children with
CFS/ME. In a recent case-control study from Norway,
children (12–18 years of age) with CFS/ME according to
strict clinical criteria had a strong reduction in health-
related quality of life compared to healthy peers [7].That study also reported that children with CFS/ME had
eight times higher risk of depressive symptoms, but that
this difference could not explain their poor quality-of-
life scores. High levels of depression (29 %) have also
been reported from a large UK cross-sectional study
among children aged 12–18 years with CFS/ME [8]. We
found higher frequencies of anxiety diagnoses among
children with CFS/ME than in our two control groups.
Another study from the UK included children with CFS/
ME 7–17 years of age and compared anxiety scores for
this group to normal population scores [9].
In a previous study using data from the NPR 2008–
2012, we have shown that there are two distinct age
peaks in the incidence of CFS/ME (age groups 10 to
19 years and 30 to 39 years) [4]. We hypothesized that
this pattern could be explained by primary exposure to
infectious agent(s) in adolescents (first age peak) and
subsequent reactivation of latent infection (second age
Bakken et al. BMC Family Practice  (2016) 17:128 Page 6 of 7peak). In the present study, we have shown that the fre-
quency of infections diagnosed in primary care is higher
prior to a diagnosis of CFS/ME than prior to a diagnosis
of T1DM, indicating that infections may indeed be
among the factors that could cause CFS/ME. In a recent
review, it was concluded that the severe fatigue that can
afflict patients with a disorders such as multiple scler-
osis, Parkinson’s disease, and systemic lupus erythemato-
sus, may be caused by peripheral inflammation and
immune activation, and that similar mechanisms may
also play a role in the development of CFS/ME [10]. In a
cohort of 301 adolescents with infectious mononucleosis
from Chicago, Illinois, 13 % met the criteria for chronic
fatigue syndrome after 6 months [11]. Also, in an adult
UK cohort consisting of patients with infectious mono-
nucleosis, influenza or tonsillitis (but no control group
without infection), the odds of clinically diagnosed fa-
tigue was found to be four times higher for infectious
mononucleosis when compared to influenza and nearly
seven times higher for infectious mononucleosis when
compared to tonsillitis [12]. These results fit well with
results from the present study, where we observed that
the greatest difference between the CFS/ME group and
either control group was for infectious mononucleosis.
However, influenza, acute tonsillitis, strep throat, and
pneumonia were also significantly more often observed
in the CFS/ME group, indicating that different infections
might trigger the development of CFS/ME. In a previ-
ous study we found a strong, positive association be-
tween pandemic influenza A (H1N1) and CFS/ME, but
no changes in risk of CFS/ME after pandemic influenza
vaccination [13]. Similarly, an earlier Norwegian study
showed no relation between vaccination against menin-
gococcal disease and CFS/ME, while a tenfold increased
risk for CFS/ME was observed after mononucleosis
with clear symptoms [14].
We found a somewhat higher frequency of asthma
among children with CFS/ME than in the T1DM and
general child population control groups. In US adults,
high rates of asthma have been described prior to the
onset of CFS [15], and from Taiwan, the risk has been
reported to increase following atopy [16]. We also ob-
served that one in ten patients with CFS/ME had been
diagnosed with migraine in primary care, which was four
times as frequent as in patients with T1DM. The link
between CFS/ME and migraine seems rather well estab-
lished. For instance, a 1.5-fold increased risk of CFS was
described in adults with migraine in another study from
Taiwan [17]. Also, in a study including two different
adult groups of patients with CFS, migraines were often
reported (39–69 %) [18]. Similar to our findings, high
frequencies of headaches and muscle pain were observed
among children (mean age 15.2 years) with CFS/ME in
Dutch paediatric departments [19].Conclusion
The findings in the present study confirm results from
previous studies in that children with CFS/ME show
higher levels of depression, anxiety, migraine, and
muscle pain than their peers. Furthermore, children with
CFS/ME are often diagnosed with infections, in particu-
lar prior to the CFS/ME diagnosis. The long time spans
observed from the first diagnosis of weakness / general
tiredness in primary care to a specialist health care diag-
nosis of CFS/ME might indicate that the treatment of
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